David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Today, Nuance Pharma ("Nuance") announced that the Hong Kong Drug Office approved Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc. The Rahway pharma giant announced the deal for the biopharmaceutical company ...

The Food and Drug Administration on Friday rejected Sunovion Pharmaceuticals’ treatment for chronic obstructive pulmonary disease. The late-stage drug is intended to serve as a long-term treatment for ...

Merck’s Maurice R. Hilleman Center for Vaccine Manufacturing photographed on Friday, Apr. 2, 2021, in Durham, N.C. Casey Toth ctoth@newsobserver.com In one of the biggest health care deals of 2025, ...

The U.S. Food and Drug Administration has approved GlaxoSmithKline’s Incruse Ellipta (umeclidinium) as a treatment for patients with chronic obsessive pulmonary disease, according to a Medscape report ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth indication. The drug is now cleared to treat certain patients with chronic ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...